Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging in patients with type 2 asthma (VESTIGE): a randomised, double-blind, placebo-controlled, phase 4 trial
Mario Castro(University of Kansas), Juby A Jacob-Nara(Sanofi (United States)), Njira Lugogo(University of Michigan), Lucía De Prado Gómez(Sanofi (Spain)), Alberto Papi(University of Ferrara), Maria Staevska(Medical University of Sofia), Arnaud Bourdin(Centre National de la Recherche Scientifique), Charles Fogarty(Spartanburg Regional Medical Center), Rufai Nadama(King Khalid University Hospital), Pai-Chien Chou(Taipei Medical University Hospital), Francisco Javier González‐Barcala(Universidade de Santiago de Compostela), Celeste Porsbjerg(Bispebjerg Hospital), Liliana Duca, Мykola Ostrovskyy(Ivano-Frankivsk National Medical University), Mei Zhang(Sanofi (United States)), Paul J. Rowe(Sanofi (United States)), Christopher E Brightling(University of Leicester), Harry Sacks(Regeneron (United States)), Yamo Deniz(Regeneron (United States)), Ana Margarida Pereira(Universidade do Porto), Xavier Soler(University of California System), Amelie Rodrigues
Cited by 67
Related Papers
Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline
|European Respiratory Journal|2017|679
Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts
|New England Journal of Medicine|2023|452
Association between Functional Small Airway Disease and FEV1 Decline in Chronic Obstructive Pulmonary Disease
|American Journal of Respiratory and Critical Care Medicine|2016|389
Benralizumab for the Prevention of COPD Exacerbations
|New England Journal of Medicine|2019|329
Eosinophilic and Noneosinophilic Asthma
|CHEST Journal|2021|262